Lobe Sciences Ltd. logo

Lobe Sciences Ltd. (LOBEF)

Market Closed
25 Jul, 20:00
OTC PINK OTC PINK
$
0. 00
+0
+11.11%
$
4.12M Market Cap
- P/E Ratio
0% Div Yield
1,053,100 Volume
0 Eps
$ 0
Previous Close
Day Range
0 0.01
Year Range
0 0.02
Want to track LOBEF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LOBEF closed Friday higher at $0, an increase of 11.11% from Thursday's close, completing a monthly increase of 138.1% or $0. Over the past 12 months, LOBEF stock gained 233.33%.
LOBEF is not paying dividends to its shareholders.
The last earnings report, released on Apr 28, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by 0%, based on the last three reports.
Lobe Sciences Ltd. has completed 1 stock splits, with the recent split occurring on Jun 10, 2022.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

LOBEF Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Lobe Sciences eyes uplisting opportunities to enhance shareholder value

Lobe Sciences eyes uplisting opportunities to enhance shareholder value

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF), a biopharmaceutical firm developing innovative medicines for rare diseases, told investors it is exploring strategic alternatives to improve shareholder value. The company said that among the alternatives it has been considering are uplisting opportunities, for example, listing on the Australian Securities Exchange or the New York Stock Exchange.

Proactiveinvestors | 1 year ago
Lobe Sciences appoints management strategy expert to board

Lobe Sciences appoints management strategy expert to board

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced that Wesley Ramjeet will join its Board of Directors in the coming months. Ramjeet, who is the chief executive and Founder of PPMT Strategic Group, brings over two decades of strategic financial expertise to the biopharmaceutical company.

Proactiveinvestors | 1 year ago
Lobe Sciences strengthens board with appointment of biopharma veteran

Lobe Sciences strengthens board with appointment of biopharma veteran

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced the appointment of Dr Frederick Sancilio to its board of directors. The company, which is focused on developing transformative medicines targeting rare diseases, highlighted that Dr Sancilio brings more than four decades of experience in pharmaceutical sciences and biopharmaceutical research to the position.

Proactiveinvestors | 1 year ago

Lobe Sciences Ltd. Dividends

LOBEF is not paying dividends to its shareholders.

Lobe Sciences Ltd. Earnings

28 Apr 2025 Date
-
Cons. EPS
-
EPS
18 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Jul 2024 Date
-
Cons. EPS
-
EPS
26 Jul 2024 Date
-
Cons. EPS
-
EPS
29 Apr 2024 Date
-
Cons. EPS
-
EPS
LOBEF is not paying dividends to its shareholders.
28 Apr 2025 Date
-
Cons. EPS
-
EPS
18 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Jul 2024 Date
-
Cons. EPS
-
EPS
26 Jul 2024 Date
-
Cons. EPS
-
EPS
29 Apr 2024 Date
-
Cons. EPS
-
EPS

Lobe Sciences Ltd. (LOBEF) FAQ

What is the stock price today?

The current price is $0.00.

On which exchange is it traded?

Lobe Sciences Ltd. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is LOBEF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 4.12M.

Has Lobe Sciences Ltd. ever had a stock split?

Lobe Sciences Ltd. had 1 splits and the recent split was on Jun 10, 2022.

Lobe Sciences Ltd. Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Dr. Frederick Dominick Sancilio M.S., Ph.D. CEO
OTC PINK Exchange
CA53946V2066 ISIN
CA Country
- Employees
- Last Dividend
10 Jun 2022 Last Split
- IPO Date

Overview

Lobe Sciences Ltd. is a pioneering biopharmaceutical entity dedicated to harnessing the potential of proprietary psychedelic substances with the aim of advancing brain health, mental wellness, and overall cognitive function. The company operates at the forefront of a burgeoning field of medicine that seeks to leverage sub-hallucinogenic dosages of psychedelic compounds to address a variety of neurological and psychiatric conditions. Initially known as Greenstar Biosciences Corp., the organization underwent a significant rebranding in November 2020, emerging as Lobe Sciences Ltd., to better reflect its focused mission and expanding research endeavors. With its headquarters firmly established in Vancouver, Canada, Lobe Sciences Ltd. represents a blend of innovative research and steadfast dedication to finding novel solutions within the health and wellness landscape.

Products and Services

  • Research and Development in Psychedelic Compounds

    At the core of Lobe Sciences Ltd.'s operations is its intensive research and development efforts surrounding psychedelic substances. These endeavors are targeted at uncovering and harnessing the therapeutic potential of sub-hallucinatory doses of these compounds. The ultimate goal is to develop treatments that can significantly improve mental health outcomes, enhance cognitive abilities, and foster an overall state of wellness in individuals facing neurological and psychiatric challenges.

Contact Information

Address: 1199 West Hastings Street
Phone: 949-505-5623